Otonomy to Present at Piper Jaffray Healthcare Conference
November 22 2017 - 7:30AM
Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company
focused on the development and commercialization of innovative
therapeutics for diseases and disorders of the ear, today announced
that David A. Weber, Ph.D., president and chief executive officer,
will present at the 29th Annual Piper Jaffray Healthcare Conference
on Wednesday, November 29, 2017 at 12:30 p.m. EST (9:30 a.m. PST)
at the Lotte New York Palace in New York City.
A live audio webcast of the presentation will be available
through the Events and Presentations page of the company's website
(www.otonomy.com).
About Otonomy
Otonomy is a biopharmaceutical company focused on the
development and commercialization of innovative therapeutics for
diseases and disorders of the ear. OTIPRIO® (ciprofloxacin otic
suspension) is approved in the United States for use during
tympanostomy tube placement surgery in pediatric patients, an sNDA
has been accepted for filing by the FDA for acute otitis externa
(AOE) and a successful End-of-Phase 2 review has been completed
with the FDA for acute otitis media with tympanostomy tubes (AOMT).
OTIVIDEX™ is a steroid in development for the treatment of
Ménière’s disease. OTO-311 is an NMDA receptor antagonist for the
treatment of tinnitus that has completed a Phase 1 clinical safety
trial. Multiple programs targeting sensorineural hearing loss
including age-related hearing loss are in preclinical development.
These programs involve the anatomical and functional restoration of
ribbon synapses, protection of hair cells from chemotoxicity, and
regeneration of hair cells. For additional information please visit
www.otonomy.com.
Contacts:Investor InquiriesWestwicke
PartnersRobert H. UhlManaging
Director858.356.5932robert.uhl@westwicke.com
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Sep 2023 to Sep 2024